25 August 2023 - Dual Clinical Efficacy of NLX-112 in Parkinson's Disease to be Presented at Movement Disorders Society Congress

NLX-112 , a ground-breaking, non-dopaminergic drug, exhibited both anti-dyskinetic and anti-parkinsonian properties in a proof-of-concept Phase 2A clinical trial. The positive findings were presented in July as a ‘Hot Topics’ oral presentation at the World Parkinson’s Congress in Barcelona, Spain ( see video ). They will also be presented at the forthcoming Movement Disorders Society Congress in Copenhagen, Denmark, on Wednesday, August 30 (Poster #1435) . The dual clinical efficacy profile of NLX-112 arises from its innovative mechanism of action. Unlike most current anti-parkinsonian medications, NLX-112 does not target the dopaminergic system, and is a highly selective, serotonin 5-HT1A receptor activator.  See the full press release .

The release as fetched from its publisher. neurolixis.com ↗